Melanoma Research

Papers
(The H4-Index of Melanoma Research is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma41
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients38
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)36
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma32
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)27
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature23
Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data22
Low-level laser irradiation potentiates anticancer activity of p-coumaric acid against human malignant melanoma cells20
Ultraviolet radiation and cutaneous melanoma: a historical perspective19
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas17
Impact of COVID-19 on melanoma diagnosis17
External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?17
Acquired lipodystrophy associated with immune checkpoint inhibitors16
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)14
The molecular profile of mucosal melanoma14
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma14
0.02723503112793